Fibrinogen coated albumin spheres to accelerate bone healing in older adults.

纤维蛋白原涂层白蛋白球可加速老年人的骨骼愈合。

基本信息

  • 批准号:
    10371263
  • 负责人:
  • 金额:
    $ 24.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-30 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Elderly people are at great risk for bone fracture and they are more likely to suffer complications during fracture healing. An inefficient healing process exposes the elderly to higher rates of delayed healing or nonunions. The slow recovery after geriatric fractures dramatically increases risks of degenerative decline, morbidity, and mortality with a negative socio-economic impact. Available solutions to facilitate bone regeneration are either invasive or show adverse events in aged people. Intravenous injectable Fibrinogen-coated Albumin nano-Spheres (FAS) are nanometer-sized spheres with a unique multivalent potential to accelerate chronic wound healing in multiple soft tissues. FAS has been shown to promote mobilization of progenitor cells of various lineages including Endothelial Progenitor Cells (EPCs), a cell population responsible also for bone regeneration, and to counteract inflammatory states. Studies conducted on young rats showed that FAS administered after fracture promotes the superior strength and structure of the healed bone. By taking advantage of this knowledge, Fibroplate Inc. proposes to investigate the efficacy of Fibrinoplate-S (FPS), a FAS formulation, as a biological agent to accelerate the healing of fractured bones in geriatric patients. If successful, FPS could represent a new therapeutic that can improve the health and functional independence of older adults. In this SBIR Phase I project Fibroplate aims to accomplish two objectives: 1) Demonstrate the efficacy of FPS in bone fracture healing in aged pre-clinical rat models. FPS will be administered after femur surgical fracture to assess the bone healing process through quantitative computed tomography, histological analysis, and biomechanical evaluation of bone strength. 2) Confirm the mobilization of stem cells induced by FPS to delve deeper into the mechanism of action. This work will be preparatory of a Phase II project where an extensive IND-enabling preclinical study will be performed to establish metabolism, dose, and toxicity, together with a long-term assessment of the bone healing process. The final goal is to obtain FDA approval of FPS as a new healing agent in age-related bone fractures. By offering an effective treatment for frail patients, Fibroplate is expected to improve and promote healthy aging.
项目概要 老年人骨折的风险很大,骨折期间更容易出现并发症 康复。低效的愈合过程使老年人面临更高的延迟愈合或骨不连发生率。这 老年骨折后恢复缓慢会显着增加退行性衰退、发病率和 死亡率带来负面的社会经济影响。促进骨再生的可用解决方案是 对老年人有侵入性或表现出不良事件。静脉注射纤维蛋白原包被白蛋白 纳米球 (FAS) 是纳米尺寸的球体,具有独特的多价潜力,可加速慢性 多个软组织的伤口愈合。 FAS 已被证明可以促进各种祖细胞的动员 谱系包括内皮祖细胞(EPC),也是负责骨再生的细胞群, 并对抗炎症状态。对幼鼠进行的研究表明,FAS 给药后 骨折可促进愈合骨骼的优异强度和结构。通过利用这些知识, Fibroplate Inc. 提议研究 Fibrinoplate-S (FPS)(一种 FAS 制剂)作为生物制剂的功效 加速老年患者骨折愈合的药物。如果成功,FPS 可能代表一种新的 可以改善老年人的健康和功能独立性的治疗方法。在这个SBIR第一期项目中 Fibroplate 旨在实现两个目标:1) 证明 FPS 在骨折愈合中的功效 老年临床前大鼠模型。股骨手术骨折后将进行 FPS 以评估骨愈合情况 通过定量计算机断层扫描、组织学分析和骨生物力学评估过程 力量。 2) 确认FPS诱导干细胞动员,深入探究其作用机制。 这项工作将为第二阶段项目做准备,该项目将进行广泛的 IND 支持的临床前研究 进行以确定代谢、剂量和毒性,以及骨愈合的长期评估 过程。最终目标是获得 FDA 批准 FPS 作为年龄相关性骨折的新型愈合剂。 通过为体弱患者提供有效的治疗,Fibroplate 有望改善和促进健康老龄化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard Yen其他文献

Richard Yen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard Yen', 18)}}的其他基金

A novel agent to manage thrombocytopenic patients with platelet transfusion refractoriness
治疗血小板输注无效的血小板减少症患者的新药
  • 批准号:
    10250676
  • 财政年份:
    2021
  • 资助金额:
    $ 24.66万
  • 项目类别:
A multivalent, easy-to-use product to mitigate and treat radiation exposure
一种多价、易于使用的产品,用于减轻和治疗辐射暴露
  • 批准号:
    10011227
  • 财政年份:
    2019
  • 资助金额:
    $ 24.66万
  • 项目类别:
A multivalent, easy-to-use product to mitigate and treat radiation exposure
一种多价、易于使用的产品,用于减轻和治疗辐射暴露
  • 批准号:
    10160769
  • 财政年份:
    2019
  • 资助金额:
    $ 24.66万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 24.66万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 24.66万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 24.66万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 24.66万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 24.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了